Monday, April 12, 2010
DRI Capital closed its Drug Royalty II at $701 million last week,
almost triple the $240 million raised in its 2006 fund, Drug Royalty I.
The firm's strategy will remain
the same: purchasing royalties on approved biopharmaceutical products with
demonstrated sales histories, according to Alex Leykikh of Atlantic-Pacific
Capital. Atlantic-Pacific was the